• Transgene reshaped its board at its combined general meeting, adding two independent directors while renewing several existing mandates.
• Dorothea Ledergerber joined as an independent director; she is multi-site head of Drug Product Operations at Siegfried Group, sits on the board of CDMO DINAMIQS, previously held leadership roles at Novartis, helped set up its first commercial cell and gene therapy production unit in Europe, and served as chief technical officer at autologous cell therapy specialist Tigen Pharma.
• Solange Peters also joined as an independent director; she is a professor and heads the Oncology Department at the University Hospital of Lausanne, chairs Medical Oncology there, focuses on thoracic tumors and immunotherapy, and sits on the board of Galenica.
• The board now has 10 members, including five independent directors and five women.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief on May 22, 2026, and is solely responsible for the information contained therein.